Effect of dose escalation on the in vivo oral absorption and disposition of glycylsarcosine in wild-type and Pept1 knockout mice

Drug Metabolism and Disposition

Volumn 39, Issue 12, 2011, Pages 2250-2257

  Jappar, Dilara ^a   Hu, Yongjun ^a   Smith, David E ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCYLSARCOSINE; PEPTIDE TRANSPORTER 1;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG TISSUE LEVEL; GENOTYPE; IN VIVO STUDY; INTESTINE; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; TISSUE DISTRIBUTION; WILD TYPE;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; DIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; MICE; MICE, KNOCKOUT; SYMPORTERS; TISSUE DISTRIBUTION;

ANIMALIA; MUS;

EID: 81855173578     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.041087     Document Type: Article

References (38)

1. Bhardwaj RK, Herrera-Ruiz D, Eltoukhy N, Saad M, and Knipp GT (2006) The functional evaluation of human peptide/histidine transporter 1 (hPHT1) in transiently transfected COS-7 cells. Eur J Pharm Sci 27:533-542. (Pubitemid 43363344)
2. Bockman DE, Ganapathy V, Oblak TG, and Leibach FH (1997) Localization of peptide transporter in nuclei and lysosomes of the pancreas. Int J Pancreatol 22:221-225. (Pubitemid 28070887)
3. Brandsch M, Knütter I, and Bosse-Doenecke E (2008) Pharmaceutical and pharmacological importance of peptide transporters. J Pharm Pharmacol 60:543-585. (Pubitemid 351589044)
4. Chen M, Singh A, Xiao F, Dringenberg U, Wang J, Engelhardt R, Yeruva S, Rubio-Aliaga I, Nässl AM, Kottra G, et al. (2010) Gene ablation for PEPT1 in mice abolishes the effects of dipeptides on small intestinal fluid absorption, short-circuit current, and intracellular pH. Am J Physiol Gastrointest Liver Physiol 299:G265-G274.
5. Daniel H and Kottra G (2004) The proton oligopeptide cotransporter family SLC15 in physiology and pharmacology. Pflugers Arch 447:610-618. (Pubitemid 38241445)
6. Fei YJ, Kanai Y, Nussberger S, Ganapathy V, Leibach FH, Romero MF, Singh SK, Boron WF, and Hediger MA (1994) Expression cloning of a mammalian proton-coupled oligopeptide transporter. Nature 368:563-566. (Pubitemid 24118776)
7. Fei YJ, Sugawara M, Liu JC, Li HW, Ganapathy V, Ganapathy ME, and Leibach FH (2000) cDNA structure, genomic organization, and promoter analysis of the mouse intestinal peptide transporter PEPT1. Biochim Biophys Acta 1492:145-154. (Pubitemid 30349190)
8. Ganapathy V, Gupta N, and Martindale RG (2006) Protein Digestion and Absorption, in Physiology of the Gastrointestinal Tract, 4th ed (Johnson LR ed), pp 1667-1692, Elsevier, Burlington.
9. Gramatté T, el Desoky E, and Klotz U (1994) Site-dependent small intestinal absorption of ranitidine. Eur J Clin Pharmacol 46:253-259. (Pubitemid 24137436)
10. Groneberg DA, Döring F, Eynott PR, Fischer A, and Daniel H (2001) Intestinal peptide transport: ex vivo uptake studies and localization of peptide carrier PEPT1. Am J Physiol Gastrointest Liver Physiol 281:G697-G704.
11. Herrera-Ruiz D and Knipp GT (2003) Current perspectives on established and putative mammalian oligopeptide transporters. J Pharm Sci 92:691-714. (Pubitemid 36396989)
12. Herrera-Ruiz D, Wang Q, Gudmundsson OS, Cook TJ, Smith RL, Faria TN, and Knipp GT (2001) Spatial expression patterns of peptide transporters in the human and rat gastrointestinal tracts, Caco-2 in vitro cell culture model, and multiple human tissues AAPS PharmSci 3:E9.
13. Hironaka T, Itokawa S, Ogawara K, Higaki K, and Kimura T (2009) Quantitative evaluation of PEPT1 contribution to oral absorption of cephalexin in rats. Pharm Res 26:40-50.
14. Hu Y, Smith DE, Ma K, Jappar D, Thomas W, and Hillgren KM (2008) Targeted disruption of peptide transporter Pept1 gene in mice significantly reduces dipeptide absorption in intestine. Mol Pharm 5:1122-1130.
15. Jappar D, Wu SP, Hu Y, and Smith DE (2010) Significance and regional dependency of peptide transporter (PEPT) 1 in the intestinal permeability of glycylsarcosine: in situ single-pass perfusion studies in wild-type and Pept1 knockout mice. Drug Metab Dispos 38:1740-1746.
16. Kim HR, Park SW, Cho HJ, Chae KA, Sung JM, Kim JS, Landowski CP, Sun D, Abd El-Aty AM, Amidon GL, et al. (2007) Comparative gene expression profiles of intestinal transporters in mice, rats and humans. Pharm Res 56:224-236. (Pubitemid 47321206)
17. Kimura T and Higaki K (2002) Gastrointestinal transit and drug absorption. Biol Pharm Bull 25:149-164. (Pubitemid 39592096)
18. Knütter I, Rubio-Aliaga I, Boll M, Hause G, Daniel H, Neubert K, and Brandsch M (2002) H+-peptide cotransport in the human bile duct epithelium cell line SK-ChA-1. Am J Physiol Gastrointest Liver Physiol 283:G222-G229. (Pubitemid 34666180)
19. Liang R, Fei YJ, Prasad PD, Ramamoorthy S, Han H, Yang-Feng TL, Hediger MA, Ganapathy V, and Leibach FH (1995) Human intestinal H+/peptide cotransporter. Cloning, functional expression, and chromosomal localization. J Biol Chem 270:6456-6463.
20. Lu H and Klaassen C (2006) Tissue distribution and thyroid hormone regulation of Pept1 and Pept2 mRNA in rodents. Peptides 27:850-857.
21. Ma K, Hu Y, and Smith DE (2011) Peptide transporter 1 is responsible for intestinal uptake of the dipeptide glycylsarcosine: studies in everted jejunal rings from wild-type and Pept1 null mice. J Pharm Sci 100:767-774.
22. Mackenzie B, Loo DD, Fei Y, Liu WJ, Ganapathy V, Leibach FH, and Wright EM (1996) Mechanisms of the human intestinal H+-coupled oligopeptide transporter hPEPT1. J Biol Chem 271:5430-5437. (Pubitemid 26083876)
23. Masaoka Y, Tanaka Y, Kataoka M, Sakuma S, and Yamashita S (2006) Site of drug absorption after oral administration: assessment of membrane permeability and luminal concentration of drugs in each segment of gastrointestinal tract. Eur J Pharm Sci 29:240-250. (Pubitemid 44602413)
24. McConnell EL, Basit AW, and Murdan S (2008) Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in-vivo experiments. J Pharm Pharmacol 60:63-70.
25. Oberle RL and Amidon GL (1987) The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon. J Pharmacokinet Biopharm 15:529-544.
26. Ocheltree SM, Shen H, Hu Y, Keep RF, and Smith DE (2005) Role and relevance of peptide transporter 2 (PEPT2) in the kidney and choroid plexus: in vivo studies with glycylsarcosine in wild-type and PEPT2 knockout mice. J Pharmacol Exp Ther 315:240-247. (Pubitemid 41380517)
27. Roberts MS, Magnusson BM, Burczynski FJ, and Weiss M (2002) Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin Pharmacokinet 41:751-790. (Pubitemid 34948196)
28. Rubio-Aliaga I and Daniel H (2008) Peptide transporters and their roles in physiological processes and drug disposition. Xenobiotica 38:1022-1042.
29. Rühl A, Hoppe S, Frey I, Daniel H, and Schemann M (2005) Functional expression of the peptide transporter PEPT2 in the mammalian enteric nervous system. J Comp Neurol 490:1-11. (Pubitemid 41099285)
30. Saito H, Okuda M, Terada T, Sasaki S, and Inui K (1995) Cloning and characterization of a rat H+/peptide cotransporter mediating absorption of beta-lactam antibiotics in the intestine and kidney. J Pharmacol Exp Ther 275:1631-1637. (Pubitemid 26129956)
31. Shen H, Ocheltree SM, Hu Y, Keep RF, and Smith DE (2007) Impact of genetic knockout of PEPT2 on cefadroxil pharmacokinetics, renal tubular reabsorption, and brain penetration in mice. Drug Metab Dispos 35:1209-1216. (Pubitemid 46956444)
32. Shen H, Smith DE, Yang T, Huang YG, Schnermann JB, and Brosius FC 3rd (1999) Localization of PEPT1 and PEPT2 proton-coupled oligopeptide transporter mRNA and protein in rat kidney. Am J Physiol 276:F658-F665. (Pubitemid 29249684)
33. Thamotharan M, Lombardo YB, Bawani SZ, and Adibi SA (1997) An active mechanism for completion of the final stage of protein degradation in the liver, lysosomal transport of dipeptides. J Biol Chem 272:11786-11790. (Pubitemid 27202745)
34. Urtti A, Johns SJ, and Sadée W (2001) Genomic structure of proton-coupled oligopeptide transporter hPEPT1 and pH-sensing regulatory splice variant. AAPS PharmSci 3:E6.
35. Walker D, Thwaites DT, Simmons NL, Gilbert HJ and Hirst BH (1998) Substrate upregulation of the human small intestinal peptide transporter, hPepT1. J Physiol 507 (Pt 3):697-706. (Pubitemid 28143571)
36. Weitschies W, Bernsdorf A, Giessmann T, Zschiesche M, Modess C, Hartmann V, Mrazek C, Wegner D, Nagel S, and Siegmund W (2005) The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen. Pharm Res 22:728-735. (Pubitemid 40768584)
37. Zhang EY, Emerick RM, Pak YA, Wrighton SA, and Hillgren KM (2004) Comparison of human and monkey peptide transporters: PEPT1 and PEPT2. Mol Pharm 1:201-210.
38. Zhou X, Thamotharan M, Gangopadhyay A, Serdikoff C, and Adibi SA (2000) Characterization of an oligopeptide transporter in renal lysosomes. Biochim Biophys Acta 1466:372-378. (Pubitemid 30312991)